Go Pro
NASDAQ:MDXH

MDxHealth Q2 2026 Earnings Report

MDxHealth logo
$0.41 -0.01 (-2.91%)
Closing price 04:00 PM Eastern
Extended Trading
$0.42 +0.01 (+3.41%)
As of 05:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MDxHealth EPS Results

Actual EPS
N/A
Consensus EPS
-$0.19
Beat/Miss
N/A
One Year Ago EPS
N/A

MDxHealth Revenue Results

Actual Revenue
N/A
Expected Revenue
$26.14 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

MDxHealth Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
Thursday, August 13, 2026
Conference Call Time
4:00PM ET

Conference Call Resources

MDxHealth Earnings Headlines

BofA: Digital Dollar Coming 2025-2030
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now. Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen. Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch.tc pixel
See More MDxHealth Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MDxHealth? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MDxHealth and other key companies, straight to your email.

About MDxHealth

MDxHealth (NASDAQ:MDXH), headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx. ConfirmMDx is an epigenetic assay performed on prostate biopsy tissue to identify men at risk of harboring occult high-grade prostate cancer following a negative biopsy result. SelectMDx is a non-invasive urine test designed to assess the likelihood of clinically significant prostate cancer before an initial biopsy, helping to reduce unnecessary procedures. Both tests are performed in MDxHealth’s CLIA-certified laboratory in the United States and its ISO-certified laboratory in Europe, and are used by urologists worldwide to guide biopsy and treatment decisions.

Founded in 2003, MDxHealth has established a global footprint, serving patients and healthcare providers across North America, Europe and select international markets through direct lab services and strategic partnerships. The company is led by President and CEO Caroline Palm, who brings extensive experience in molecular diagnostics and life sciences. MDxHealth is publicly traded on the Nasdaq under the ticker symbol MDXH.

View MDxHealth Profile